<DOC>
	<DOCNO>NCT02506868</DOCNO>
	<brief_summary>The purpose study prove equivalence efficacy safety BCD-066 Aranesp® treatment anemia end-stage chronic kidney disease patient dialysis .</brief_summary>
	<brief_title>Safety Efficacy Study BCD-066 Compared Aranesp® Anemia Treatment Chronic Kidney Disease Patients</brief_title>
	<detailed_description>In study CKD patient dialysis previously treat short-acting epoetins switch one darbepoetin alfa product - BCD-066 ( experimental arm ) Aranesp ( active comparator ) maintain previously achieve target level hemoglobin ( 100-120 g/l ) . Patients treat 52 week . IV iron supplementation provide maintain serum ferritin level 500 µg/l accord KDIGO Anemia Guidelines ( 2012 ) .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Written inform consent Age 18 75 year Endstage kidney disease Need dialysis least 3 month enrollment Need least 12 hour standard dialysis procedure weekly Regular rHuEpo ( epoetin alfa , epoetin beta , darbepoetin alfa ) administration 1 , 2 3 time week ( stable dose , stable frequency ) least 3 month enrollment Target hemoglobin level ( 100120 g/l ) least 3 month enrollment Effective dialysis ( Kt/v≥1,2 ) TSAT ≥20 % , Serum ferritin &gt; 200 ng/ml Patients sexual partner childbearing potential must implement reliable contraceptive measure study treatment , start 4 week prior administration first dose investigational product 4 week last dose investigational product . This requirement apply participant undergone surgical sterilization . Reliable contraceptive measure include two method contraception , include one barrier method Patients able follow Protocol procedure ( accord Investigator 's assessment ) Any cause anemia except renal anemia , include folate B12 deficiency , chronic blood loss , aluminium intoxication , sicklecell anemia , chronic disease anemia ( CRP 20 mg/l ) , refractory anemia blast cell peripheral blood Lupus nephritis kidney disease due systemic vasculitis Platelet count 100х10^9 cells/l Hemoglobin 120 g/l 100 g/l Scheduled kidney transplant study participation period Binding/neutralizing antibody erythropoetin/darbepoetin History severe allergic reaction Vaccination less 8 week enrollment Liver cirrhosis portal hypertension and/or splenomegaly and/or ascitis HIV infection , active HBV , HCV ALT , AST level 3x ULN Bone marrow fibrosis Congestive heart failure ( Grade IV NYHA ) Resistant arterial hypertension Unstable angina Hemoglobinopathy , MDS , hematologic malignancy PRCA Severe secondary hyperparathyroidism ( PTH &gt; 9x ULN ) GI bleed history Thrombotic event history ( myocardial infarction , stroke , TIA , DVT , PATE ) less 6 month enrollment Acute hemolysis history Seizures , include epilepsy Major surgery less 1 month enrollment Blood transfusion less 3 month enrollment Acute inflammatory disease exacerbation chronic inflammation include septic aseptic inflammation focus Severe psychiatric disorder History malignancy , exclude appropriately treat basal cell carcinoma cervical carcinoma situ Alcohol drug abuse Hypersensitivity darbepoetin alfa component study drug Simultaneous participation trial less 3 month enrollment Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>darbepoetin alfa</keyword>
</DOC>